Dexcom (DXCM) Common Equity (2010 - 2026)

Dexcom (DXCM) has 17 years of Common Equity data on file, last reported at $3.0 billion in Q1 2026.

• Quarterly Common Equity rose 30.46% year-over-year to $3.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 billion (up 30.46% YoY) and the FY2025 annual result came in at $2.7 billion, up 30.6% from the prior year.
• Common Equity rose to $3.0 billion in Q1 2026 per DXCM's latest filing, from $2.7 billion in the prior quarter.
• Across five years, Common Equity topped out at $3.0 billion in Q1 2026 and bottomed at $1.8 billion in Q3 2022.
• The 5-year median for Common Equity is $2.2 billion (2024), against an average of $2.3 billion.
• The widest annual swing landed in 2024, when Common Equity declined 12.74%; it then surged 37.75% in 2025.
• Tracing DXCM's Common Equity over 5 years: stood at $2.1 billion in 2022, then fell by 2.96% to $2.1 billion in 2023, then increased by 1.64% to $2.1 billion in 2024, then soared by 30.6% to $2.7 billion in 2025, then increased by 7.68% to $3.0 billion in 2026.
• Per Business Quant, the three latest DXCM Common Equity figures stand at $3.0 billion (Q1 2026), $2.7 billion (Q4 2025), and $2.7 billion (Q3 2025).

Peer Comparison